Active-site molecular docking of nigellidine with nucleocapsid–NSP2–MPro of COVID-19 and to human IL1R–IL6R and strong antioxidant role of Nigella sativa in experimental rats. (28th May 2022)
- Record Type:
- Journal Article
- Title:
- Active-site molecular docking of nigellidine with nucleocapsid–NSP2–MPro of COVID-19 and to human IL1R–IL6R and strong antioxidant role of Nigella sativa in experimental rats. (28th May 2022)
- Main Title:
- Active-site molecular docking of nigellidine with nucleocapsid–NSP2–MPro of COVID-19 and to human IL1R–IL6R and strong antioxidant role of Nigella sativa in experimental rats
- Authors:
- Maiti, Smarajit
Banerjee, Amrita
Nazmeen, Aarifa
Kanwar, Mehak
Das, Shilpa - Abstract:
- Abstract: The recent outbreak of SARS CoV-2 has changed the global scenario of human lives/economy. A significant number of the non-survivors showed cardiac renal vasculature dysfunction. A 'cytokine storm' namely, interleukin IL6–IL1 receptors, i.e. IL6R–IL1R over-functioning was reported. Here, nigellidine, an indazole alkaloid and key component of Nigella sativa L . (NS) commonly known as black cumin seed was analysed for COVID-19 protein targeting and IL1R–IL6R inhibition through molecular docking study and biochemical study in experimental rat to evaluate antioxidative capacity. The NMR/X-ray crystallographic/electron microscopic structures of COVID-19 main protease (6LU7)/spike glycoprotein (6vsb)/NSP2 (QHD43415_2)/nucleocapsid (QHD43423), human IL1R (1itb)-IL6R (1pm9) from PDB were retrieved analysed for receptor–ligand interaction. Then, those structures were docked with nigellidine using AutoDock and PatchDock server. A brief comparison was made with nigellicine thymoquinone from N. sativa. Where nigellidine showed highest binding energy of −6.6 kcal/mol, ligand efficiency of −0.3 with COVID19 Nsp2 forming bonds with amino acid CYS240 present in binding pocket. Nigellidine showed strong interaction with main protease (BE: –6.38/LE: –0.29). Nigellidine showed affinity to IL1R (–6.23). The NS treated rat showed marked decline in ALP-SGPT-SGOT-malondialdehyde (MDA) than the basal levels. From the Western blot and activity analysis, it was observed that NigellidineAbstract: The recent outbreak of SARS CoV-2 has changed the global scenario of human lives/economy. A significant number of the non-survivors showed cardiac renal vasculature dysfunction. A 'cytokine storm' namely, interleukin IL6–IL1 receptors, i.e. IL6R–IL1R over-functioning was reported. Here, nigellidine, an indazole alkaloid and key component of Nigella sativa L . (NS) commonly known as black cumin seed was analysed for COVID-19 protein targeting and IL1R–IL6R inhibition through molecular docking study and biochemical study in experimental rat to evaluate antioxidative capacity. The NMR/X-ray crystallographic/electron microscopic structures of COVID-19 main protease (6LU7)/spike glycoprotein (6vsb)/NSP2 (QHD43415_2)/nucleocapsid (QHD43423), human IL1R (1itb)-IL6R (1pm9) from PDB were retrieved analysed for receptor–ligand interaction. Then, those structures were docked with nigellidine using AutoDock and PatchDock server. A brief comparison was made with nigellicine thymoquinone from N. sativa. Where nigellidine showed highest binding energy of −6.6 kcal/mol, ligand efficiency of −0.3 with COVID19 Nsp2 forming bonds with amino acid CYS240 present in binding pocket. Nigellidine showed strong interaction with main protease (BE: –6.38/LE: –0.29). Nigellidine showed affinity to IL1R (–6.23). The NS treated rat showed marked decline in ALP-SGPT-SGOT-malondialdehyde (MDA) than the basal levels. From the Western blot and activity analysis, it was observed that Nigellidine (sulphuryl group drug) showed no impact on phenol-catalysing ASTIV and steroid-catalysing oestrogen-sulphotransferase expressions and activities in liver tissue and thus has no influence in sulphation-mediated adverse metabolic processes. Conclusively, nigellidine has hepato-reno-protective/antioxidant-immunomodulatory/anti-inflammatory activities with inhibit potentials of COVID-19 proteins. Further validation is necessary. … (more)
- Is Part Of:
- Journal of drug targeting. Volume 30:Number 5(2022)
- Journal:
- Journal of drug targeting
- Issue:
- Volume 30:Number 5(2022)
- Issue Display:
- Volume 30, Issue 5 (2022)
- Year:
- 2022
- Volume:
- 30
- Issue:
- 5
- Issue Sort Value:
- 2022-0030-0005-0000
- Page Start:
- 511
- Page End:
- 521
- Publication Date:
- 2022-05-28
- Subjects:
- SARS CoV-2 proteins -- cytokine -- nigellidine -- inhibition -- molecular docking -- cytotoxicity test -- rat model
Drug delivery systems -- Periodicals
Drug Delivery Systems
Vehicles
Drug Administration Routes
Drug Evaluation
615.7 - Journal URLs:
- http://informahealthcare.com/loi/drt ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/1061186X.2020.1817040 ↗
- Languages:
- English
- ISSNs:
- 1061-186X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4970.582000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21650.xml